Literature DB >> 12808123

Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin.

Rosario Gil-Benso1, Concha Lopez-Gines, José Antonio López-Guerrero, Carmen Carda, Robert C Callaghan, Samuel Navarro, Jaime Ferrer, Antonio Pellín, Antonio Llombart-Bosch.   

Abstract

Chondrosarcomas are malignant cartilage-forming tumors that represent the second most common malignant solid tumor of bone. These biologically poorly understood neoplasms vary considerably in clinical presentation and biologic behavior. Chemotherapy and radiation therapy are generally ineffective. Here we describe the establishment and characterization of a new human chondrosarcoma cell line named ch-2879, and we compare the cell line with its tumor of origin. The cell line was established from a recurrent grade 3 chondrosarcoma of the chest wall and characterized by growth kinetics and morphologic studies. Immunocytochemistry and RT-PCR were performed to examine the expression of cartilage-specific phenotypes. Genetic characterization was performed using cytogenetics, fluorescence in situ hybridization, flow cytometry, and molecular techniques for analysis of the genes implicated in cell cycle control, amplification of MDM2, CDK4, and Cyclin D1, and mutations in the p53 gene. ch-2879 cells were subcultured for more than 80 passages. They expressed vimentin, HNK-1, HBA-71, Ki-67, cyclin D1, Fli-1, S-100, p21, p27, and p53 and were negative for cytokeratin, EMA, p14, p16, MDM2, Rb, and c-erb-b2 antigens. Cytogenetically the recurrent tumor showed a hyperhaploid karyotype with clonal numerical and structural abnormalities. The sole structural abnormality was a chromosome derivative of a t(1;21) translocation. The cell line at passage 3 showed two populations: the hyperhaploid and an exactly duplicated, hypotriploid population. After the 18th passage, only the hypotriploid population was present. The cells expressed collagen 2. Molecular comparison of the primary and recurrent tumor evidenced an in vivo molecular change consisting of a deletion of 9p21 genes in the recurrence, probably caused by a selection process. Because of its gene expression profile, including expression of genes implicated in chondrogenesis in uncoated plastic dishes, this cell line may prove useful for cellular and molecular studies as well as studies of chondrosarcoma characterization and treatment.

Entities:  

Mesh:

Year:  2003        PMID: 12808123     DOI: 10.1097/01.lab.0000073131.34648.ea

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

1.  New cell lines with chondrocytic phenotypes from human chondrosarcoma.

Authors:  Ikuo Kudawara; Nobuhito Araki; Akira Myoui; Yoichi Kato; Atsumasa Uchida; Hideki Yoshikawa
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

2.  Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease.

Authors:  Thomas Kalinski; Sabine Krueger; Antje-Friederike Pelz; Peter Wieacker; Roland Hartig; Martin Röpke; Regine Schneider-Stock; Frank Dombrowski; Albert Roessner
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

3.  An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.

Authors:  Jolieke G van Oosterwijk; Jacqueline R M Plass; Danielle Meijer; Ivo Que; Marcel Karperien; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2014-10-21       Impact factor: 4.064

4.  Characterization of a new human melanoma cell line with CD133 expression.

Authors:  Rosario Gil-Benso; Carlos Monteagudo; Miguel Cerdá-Nicolás; Robert C Callaghan; Sandra Pinto; Alicia Martínez-Romero; Ana Pellín-Carcelén; Teresa San-Miguel; Juan C Cigudosa; Concha López-Ginés
Journal:  Hum Cell       Date:  2012-04-13       Impact factor: 4.174

5.  Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Authors:  Silvia Calabuig-Fariñas; Rosario Gil Benso; Karoly Szuhai; Isidro Machado; José Antonio López-Guerrero; Danielle de Jong; Amando Peydró; Teresa San Miguel; Lara Navarro; Antonio Pellín; Antonio Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

6.  Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.

Authors:  Yvonne M Schrage; Liesbeth Hameetman; Karoly Szuhai; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes.

Authors:  Cathelijn J F Waaijer; Carlos E de Andrea; Andrew Hamilton; Jolieke G van Oosterwijk; Sally E Stringer; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2012-08-18       Impact factor: 4.064

8.  The in ovo CAM-assay as a xenograft model for sarcoma.

Authors:  Gwen M L Sys; Lore Lapeire; Nikita Stevens; Herman Favoreel; Ramses Forsyth; Marc Bracke; Olivier De Wever
Journal:  J Vis Exp       Date:  2013-07-17       Impact factor: 1.355

9.  Characterization of a new glioblastoma cell line, GB-val4, with unusual TP53 mutation.

Authors:  Lisandra Muñoz-Hidalgo; Teresa San-Miguel; Javier Megías; Rosario Gil-Benso; Miguel Cerdá-Nicolás; Concha López-Ginés
Journal:  Hum Cell       Date:  2019-08-06       Impact factor: 4.174

10.  Characterization of the new human pleomorphic undifferentiated sarcoma TP53-null cell line mfh-val2.

Authors:  Rosario Gil-Benso; Javier Megías; Teresa San-Miguel; Sandra Pinto; Robert C Callaghan; Concha López-Ginés; Miguel Cerdá-Nicolás
Journal:  Cytotechnology       Date:  2017-07-04       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.